Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Niacin controlled release/laropiprant - Merck

Drug Profile

Niacin controlled release/laropiprant - Merck

Alternative Names: Cordaptive; ER niacin/laropiprant; ERN/LRPT - Merck; Extended-release niacin/immediate-release laropiprant; Laropiprant/ER niacin; Laropiprant/extended-release niacin; Laropiprant/nicotinic acid; MK-0524A; MK-524A; Nicotinic acid/laropiprant; Pelzont; Tredaptive; Tredaptive Extended-release tab; Trevaclyn

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; Merck Sharp & Dohme
  • Class Antihyperlipidaemics; Indoles; Nicotinic acids; Small molecules
  • Mechanism of Action GPR109A receptor agonists; GPR109B receptor agonists; Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Dyslipidaemias; Hypercholesterolaemia
  • Discontinued Atherosclerosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 09 Mar 2013 Withdrawn for Dyslipidaemias in Hong Kong (PO)
  • 09 Mar 2013 Withdrawn for Dyslipidaemias in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top